This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kirtane, A. J. Search for Related Content PubMed PubMed Citation Articles by Kirtane, A. J.

Correlates of Bleeding Events Among Moderate- to High-Risk Patients Undergoing Percutaneous Coronary Intervention and Treated With Eptifibatide

Observations From the PROTECT–TIMI-30 Trial

Ajay J. Kirtane, MD, SM^_*, Gregory Piazza, MD^_*, Sabina A. Murphy, MPH, Daniela Budiu, MD, David A. Morrow, MD, MPH, FACC, David J. Cohen, MD, MSc^_*, Eric Peterson, MD, MPH, FACC, Nasser Lakkis, MD, FACC, Howard C. Herrmann, MD, FACC^||, Theresa M. Palabrica, MD^¶, C. Michael Gibson, MS, MD, FACC^_*,,_* for the TIMI Study Group

^_* Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center
Cardiovascular Division, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts
Duke Clinical Research Institute, Durham, North Carolina
Ben Taub General Hospital, Houston, Texas
^|| University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
^¶ Millennium Pharmaceuticals, Cambridge, Massachusetts

View larger version (11K): [in a new window]   Figure 1 Relation of age and bleeding.

View larger version (16K): [in a new window]   Figure 2 Relation of creatinine clearance (CrCl) and bleeding. IQ = interquartile range.

View larger version (8K): [in a new window]   Figure 3 Cumulative distribution function of duration of eptifibatide infusion in patients (pts) with bleeding. IQ = interquartile range.

View larger version (13K): [in a new window]   Figure 4 Relation of dose adjustment of eptifibatide infusion to bleeding. CrCl = creatinine clearance.